Lantus

Primary Uses

Lantus is prescribed to help manage blood glucose levels in people with diabetes. It is approved for use in the following situations:

• Type 1 Diabetes: It is used in adults and children at least 2 years of age.
• Type 2 Diabetes: It is used in adults to help maintain stable blood sugar levels.

Role in Diabetes Management

Lantus is a basal insulin, meaning it is designed to provide a slow, steady release of insulin into the bloodstream over a 24-hour period. This helps keep blood sugar levels consistent between meals and during sleep. While it provides a baseline level of insulin, some patients may also require separate injections of short-acting insulin at mealtimes to manage blood sugar spikes after eating.

Limitations of Use

Lantus is not intended for the treatment of diabetic ketoacidosis, a life-threatening complication of diabetes. This condition requires immediate medical attention and is typically treated with fast-acting intravenous insulin in a clinical setting.

Mechanism of Action

Lantus contains insulin glargine, a man-made form of insulin. It works by replacing the insulin that the body would normally produce. Its primary function is to help move sugar (glucose) from the bloodstream into the body's cells, where it is used for energy. Additionally, it helps regulate glucose levels by signaling the liver to stop producing more sugar.

Steady Release and Duration

Lantus is classified as a long-acting, or basal, insulin. After it is injected under the skin, the medication forms small clusters (micro-precipitates) that dissolve slowly. This allows for a gradual and steady release of insulin into the bloodstream. Key characteristics of how it works include:

• Slow Onset: It typically begins to lower blood sugar several hours after injection.
• No Peak: Unlike short-acting insulins, Lantus is designed to have a relatively flat profile, meaning it does not have a major "peak" or surge in activity.
• Extended Duration: It provides a consistent level of insulin for approximately 24 hours.

By maintaining a steady level of insulin in the system, Lantus helps keep blood sugar levels stable between meals and throughout the night.

Common Side Effects

The most common side effect of Lantus is hypoglycemia (low blood sugar). Other frequently reported side effects include:

• Weight gain
• Injection site reactions, such as redness, swelling, or itching
• Lipodystrophy, which is the thickening or pitting of the skin at the injection site
• Swelling in the hands, ankles, or feet (edema)
• Symptoms of a common cold or upper respiratory tract infection

Serious Side Effects

While less common, some side effects can be severe and require immediate medical attention:

• Severe allergic reactions: Symptoms may include a whole-body rash, shortness of breath, rapid pulse, sweating, or swelling of the face, tongue, or throat.
• Low potassium (hypokalemia): This condition can cause muscle weakness, cramps, or abnormal heart rhythms.
• Severe hypoglycemia: Very low blood sugar can lead to confusion, seizures, or loss of consciousness.
• Heart failure: Using Lantus with certain other diabetes medications called thiazolidinediones (TZDs) may increase the risk of heart failure.

Early signs of low blood sugar include shakiness, sweating, fast heartbeat, blurred vision, and hunger. Patients should be aware of these symptoms and follow their healthcare provider's instructions for managing them.

Hypoglycemia

Low blood sugar (hypoglycemia) is the most common side effect of insulin therapy and can be life-threatening. The timing of hypoglycemia usually reflects the time-action profile of the insulin formulation. Monitoring blood glucose levels is essential for all patients using this medication.

Hypersensitivity and Allergic Reactions

Severe, life-threatening allergic reactions, including anaphylaxis, can occur. Symptoms may include a whole-body rash, shortness of breath, wheezing, fast pulse, or sweating. If a serious reaction occurs, the medication should be discontinued and medical help sought immediately.

Hypokalemia

Insulin can cause potassium levels in the blood to drop (hypokalemia). If left untreated, this can lead to respiratory paralysis, heart rhythm problems, and death. Monitoring potassium levels may be necessary for patients at risk.

Medication Errors and Sharing

To prevent the spread of bloodborne pathogens, Lantus SoloStar pens or syringes must never be shared between patients, even if the needle is changed. Patients should always check the insulin label before injection to avoid accidental mix-ups between different types of insulin.

Fluid Retention and Heart Failure

When used in combination with certain other diabetes medications called thiazolidinediones (TZDs), fluid retention and heart failure may occur. Patients should be monitored for signs of heart failure, such as shortness of breath or swelling of the ankles and feet.

Injection Site Reactions

Repeated injections in the same spot can cause skin thickening, pits, or lumps (lipodystrophy or localized cutaneous amyloidosis). Rotating the injection site within the same region helps reduce the risk of these skin changes and ensures the insulin is absorbed correctly.

Pregnancy

Research involving pregnant women has not shown an increased risk of major birth defects, miscarriage, or other adverse outcomes for the mother or the baby when using Lantus. Maintaining stable blood glucose levels is essential during pregnancy to reduce the risk of complications for both the parent and the developing fetus.

Insulin requirements typically fluctuate throughout pregnancy and the period immediately following delivery:

• First trimester: Insulin needs may decrease.
• Second and third trimesters: Insulin needs usually increase.
• Postpartum: Insulin requirements often drop rapidly after the baby is born.

Breastfeeding

It is not known whether insulin glargine passes into human breast milk. However, because insulin is a natural substance found in breast milk and is generally broken down in the infant's digestive tract, it is usually considered safe to use while nursing. Breastfeeding can also affect blood sugar levels, which may necessitate further adjustments to the insulin dose.

Individuals who are pregnant, planning to become pregnant, or breastfeeding should discuss their treatment plan with a healthcare provider to ensure blood sugar is monitored closely and dosages are adjusted appropriately.

Dosage Forms

Lantus is a clear, colorless liquid solution intended for subcutaneous injection. It is available in two main delivery formats:

• Multi-dose Vial: A glass vial containing the insulin solution, typically used with a separate insulin syringe for administration.
• SoloStar Prefilled Pen: A disposable, single-patient-use injection device that contains the medication and allows for dose selection.

FDA Approval and Indications

Lantus was first approved by the U.S. Food and Drug Administration (FDA) in 2000. It is indicated to improve glycemic control in the following populations:

• Adults and pediatric patients with type 1 diabetes mellitus.
• Adults with type 2 diabetes mellitus.

Lantus is not indicated for the treatment of diabetic ketoacidosis.

Safety and Regulatory Communications

Lantus does not currently carry a Boxed Warning, which is the FDA’s most serious type of warning. There is also no Risk Evaluation and Mitigation Strategy (REMS) required for this medication.

In the past, the FDA evaluated post-marketing studies regarding a potential link between insulin glargine and an increased risk of cancer. After a thorough review, the FDA concluded in 2011 that the evidence was inconclusive and did not show an increased risk of cancer associated with the use of Lantus. The agency continues to monitor the safety profile of all insulin products.

Biosimilar and Interchangeable Status

The FDA has approved biosimilar versions of insulin glargine. Some of these products have been granted an "interchangeable" designation, which allows them to be substituted for Lantus at the pharmacy level without a new prescription from a healthcare provider, subject to state-specific laws.

How Lantus Works

Lantus contains insulin glargine, a long-acting man-made version of the insulin naturally produced by the body. It is designed to lower blood glucose levels by facilitating the movement of sugar from the blood into cells, where it can be used for energy. It also prevents the liver from producing more sugar.

Basal Insulin Characteristics

Unlike rapid-acting insulins, Lantus is considered a basal insulin because it provides a consistent level of insulin throughout the day and night. Key characteristics include:

• Duration: It typically works for approximately 24 hours.
• No Peak: It does not have a pronounced peak of activity, which helps maintain stable blood sugar levels between meals and during sleep.
• Administration: It is injected subcutaneously (under the skin) once daily at the same time each day.

Usage in Diabetes Management

Lantus is used for both type 1 and type 2 diabetes. In people with type 1 diabetes, it must be used in combination with a short-acting insulin. In people with type 2 diabetes, it may be used alone or with oral glucose-lowering medications or other types of insulin.

It is important to note that Lantus should not be used to treat diabetic ketoacidosis, as a faster-acting insulin is required for that condition.